Halozyme Therapeutics, Inc. (LON:0J2O)
77.11
-2.98 (-3.72%)
Feb 12, 2026, 5:07 PM GMT
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $354.26M USD in the quarter ending September 30, 2025, with 22.12% growth. This brings the company's revenue in the last twelve months to $1.24B, up 31.19% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.24B
Revenue Growth
+31.19%
P/S Ratio
7.41
Revenue / Employee
$3.55M
Employees
350
Market Cap
6.85B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
| Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
| Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
| Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
| Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
| Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
| Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
| Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
| Dec 31, 2010 | 13.62M | -47.19K | -0.35% |
| Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
| Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
| Dec 31, 2007 | 3.80M | 2.82M | 287.02% |
| Dec 31, 2006 | 981.75K | 854.54K | 671.76% |
| Dec 31, 2005 | 127.21K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| CVS Group | 673.20M |
| Genus | 672.80M |
Halozyme Therapeutics News
- 9 days ago - Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth - Seeking Alpha
- 10 days ago - IBD Stock Of The Day Halozyme Eyes Two Buy Points; How It's 'Layering' Up For Future Growth - Investor's Business Daily
- 15 days ago - Halozyme Therapeutics Inc Investor Call Transcript - GuruFocus
- 15 days ago - Halozyme Therapeutics Projects Sustained Growth Well Into 2040 - Benzinga
- 15 days ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 15 days ago - Halozyme Therapeutics, Inc. (HALO) 2025 Sales/ Trading Statement Call - Slideshow - Seeking Alpha
- 15 days ago - Enhanced Guidance Boosts Halozyme's (HALO) Growth Prospects - GuruFocus
- 15 days ago - Halozyme (HALO) Projects Strong Revenue Growth for FY26 - GuruFocus